Content about Pharmacist Society

January 10, 2014

The Food and Drug Administration has approved a generic drug for high blood pressure made by Actavis, the company said Friday.

DUBLIN — The Food and Drug Administration has approved a generic drug for high blood pressure made by Actavis, the company said Friday.

Actavis announced the approval of telmisartan immediate-release tablets in the 20-mg, 40-mg and 80-mg strengths, which it intends to release immediately.

January 10, 2014

The Food and Drug Administraiton has approved a liquid formulation of an HIV drug made by Merck, the company said.

WHITEHOUSE STATION, N.J. — The Food and Drug Administraiton has approved a liquid formulation of an HIV drug made by Merck, the company said.

Merck announced the approval of Isentress (raltegravir) for oral suspension, aimed at small children with HIV. The drug may be used by patients as young as four weeks, and the full line of formulations of Isentress now includes the orlal suspension, as well as chewable tablets and film--coated tablets. The company plans to launch the oral suspension in the third quarter of this year.

January 9, 2014

Administering high-touch, expensive and complex medications to patients intravenously in their homes — or in a setting other than a hospital — is essentially a large-scale bid to “reduce costs by transferring non-self-administered drugs to the most cost-effective and clinically appropriate site of care,” said pharmacist Michael Einodshofer, senior director of specialty strategy and innovation at Walgreens Specialty Pharmacy.

Administering high-touch, expensive and complex medications to patients intravenously in their homes — or in a setting other than a hospital — is essentially a large-scale bid to “reduce costs by transferring non-self-administered drugs to the most cost-effective and clinically appropriate site of care,” said pharmacist Michael Einodshofer, senior director of specialty strategy and innovation at Walgreens Specialty Pharmacy.

January 9, 2014

Amneal Pharmaceuticals has appointed Rochelle Fuhrmann as CFO, the generic drug maker said Thursday.

BRIDGEWATER, N.J. — Amneal Pharmaceuticals has appointed Rochelle Fuhrmann as CFO, the generic drug maker said Thursday.

Fuhrmann was formerly SVP finance at Warner Chilcott, where she was responsible for the oversight and direction of the finance and accounting functions, including corporate accounting, financial planning and analysis, tax, treasury, risk management, internal audit and investor relations. She began working at Warner Chilcott in June 2006 and was promoted to SVP in January 2011.

January 9, 2014

A pharmacy professor and compounding pharmacy owner are candidates for president-elect of the American Pharmacists Association for 2015-2016, the group said.

WASHINGTON — A pharmacy professor and compounding pharmacy owner are candidates for president-elect of the American Pharmacists Association for 2015-2016, the group said.

The APhA said the candidates for the position are Virginia Commonwealth University School of Pharmacy professor and community pharmacy residency program director Jean-Venable Goode and Newport Beach, Calif.-based Westcliff Compounding Pharmacy owner Michael Pavlovich. Members will have the opportunity to meet the candidates at the APhA Annual Meeting and Exposition in Orlando, Fla., in March.

January 9, 2014

Bi-Lo and Winn-Dixie will cover initial prescription costs for customers who have enrolled in the health insurance marketplaces, but don't yet have their identification cards, the chains said.

GREENVILLE, S.C. — Bi-Lo and Winn-Dixie will cover initial prescription costs for customers who have enrolled in the health insurance marketplaces, but who don't yet have their identification cards, the chains said.

The supermarket chains, both banners owned by Bi-Lo Holdings, will offer 30-day supplies of most prescription drugs at no upfront cost to health insurance marketplace enrollees until Jan. 31.

January 9, 2014

A deal announced last month between CVS Caremark and Cardinal Health created a joint venture that the companies said would be the largest generic drug sourcing entity in the United States.

A deal announced last month between CVS Caremark and Cardinal Health created a joint venture that the companies said would be the largest generic drug sourcing entity in the United States.

Each company will have a 50% stake in the joint venture, contributing its respective sourcing and supply chain expertise. The deal also included an extension of Cardinal Health’s existing pharmaceutical distribution agreement with CVS Caremark through June 2019.

January 9, 2014

Sam's Club is offering free health screenings for the New Year on Saturday, the club retailer said.

BENTONVILLE, Ark. – Sam's Club is offering free health screenings for the New Year on Saturday, the club retailer said.

The screenings are available at the 581 Sam's Club locations that operate a pharmacy and will take place from 11 a.m. until 3 p.m. The screenings are the first of a series of monthly screenings that will take place on the second Saturday of each month through October.

Screenings include glucose, cholesterol, blood pressure, body mass index and vision.

January 9, 2014

Forest Labs will buy privately owned drug maker Aptalis for $2.9 billion, Forest said Thursday.

NEW YORK — Forest Labs will buy privately owned drug maker Aptalis for $2.9 billion, Forest said Thursday.

Aptalis specializes in making drugs for gastrointestinal disorders and cystic fibrosis, with sales of $688 million in fiscal year 2013. More than 60% of its sales come from the ulcer treatment Carafate (sucralfate), the inflammatory bowel disease treatment Canasa (melamine) and the cystic fibrosis drug Zenpep (pancrelipase).

January 9, 2014

Rather than take vacation for Christmas and New Year’s, the editors of DSN worked to compile a list of the top 10 trends that will shake up the business in 2014.

Rather than take vacation for Christmas and New Year’s, the editors of DSN worked to compile a list of the top 10 trends that will shake up the business in 2014.

Clinics explode onto scene

Keep a close eye on retail-based health clinics come 2014.

The convenient care industry has come far since hitting the scene in 2000 and today — with nearly 1,500 clinics nationwide — they are proving their importance within the changing healthcare landscape.

January 9, 2014

Mylan has launched a generic drug for preventing rejection of transplanted organs, the company said Thursday.

PITTSBURGH — Mylan has launched a generic drug for preventing rejection of transplanted organs, the company said Thursday.

The generic drug maker announced the launch of mycophenolic acid delayed-release tablets in the 180-mg and 360-mg strengths. The drug is a generic version of Novartis' Myfortic. As the first company to file a completed regulatory approval application for the generic, Mylan is entitled to 180 days in which to compete exclusively against Novartis' product before the Food and Drug Administration can approve additional generic versions.

January 9, 2014

Vulnerable patients, including seniors and cancer patients, suffer from lack of access to needed painkillers as efforts to combat diversion and misuse of controlled substances often result in drugs not getting into the hands of those who need them, according to a new pharmacist survey by the National Community Pharmacists Association.

ALEXANDRIA, Va. —Vulnerable patients, including seniors and cancer patients, suffer from lack of access to needed painkillers as efforts to combat diversion and misuse of controlled substances often result in drugs not getting into the hands of those who need them, according to a new pharmacist survey by the National Community Pharmacists Association. 

January 9, 2014

The clinical development director of Rx.com Pharmacy Benefit Coalition is among the first few dozen pharmacists to receive a specialty pharmacy certification, the company said.

FORT WORTH, Texas — The clinical development director of Rx.com Pharmacy Benefit Coalition is among the first few dozen pharmacists to receive a specialty pharmacy certification, the company said.

January 9, 2014

A confluence of healthcare trends has expanded a lucrative, if challenging, opportunity for pharmacies able to invest in its potential.

A confluence of healthcare trends has expanded a lucrative, if challenging, opportunity for pharmacies able to invest in its potential.

January 9, 2014

Ninety percent of people today want to have a say in important decisions regarding their health care, but only a small percentage are certain they'll have the recommended amount of savings needed to cover health expenses after retirement, according to a new study.

ANN ARBOR, Mich. – Ninety percent of people today want to have a say in important decisions regarding their health care, but only a small percentage are certain they'll have the recommended amount of savings needed to cover health expenses after retirement, according to a new study.

January 9, 2014

The head of the country's largest e-prescribing network is stepping down, the company said Thursday.

ARLINGTON, Va. — The head of the country's largest e-prescribing network is stepping down, the company said Thursday.

Surescripts announced that president and CEO Harry Totonis would leave the company in March. Totonis began with the company following its 2008 merger with RxHub.

Surescripts' board of directors is retaining an executive search firm to find a successor, and a spokeswoman for the company told DSN that it was actively looking for a replacement with Totonis' help, and did not have plans to appoint an interim CEO at this time.

January 9, 2014

Teva Pharmaceutical Industries has appointed Erez Vigodman as president and CEO, the Israeli drug maker said Thursday.

JERUSALEM — Teva Pharmaceutical Industries has appointed Erez Vigodman as president and CEO, the Israeli drug maker said Thursday.

Vigodman will replace acting president and CEO Eyal Desheh, who will return to his previous position as group EVP and CFO. Desheh took the interim position after the departure of former president and CEO Jeremy Levin in October 2013.

January 8, 2014

Japanese drug maker Daiichi Sankyo is seeking Food and Drug Administration approval for a once-daily tablet to reduce the risk of stroke in patients with atrial fibrillation and treatment of other conditions.

PARSIPPANY, N.J. — Japanese drug maker Daiichi Sankyo is seeking Food and Drug Administration approval for a once-daily tablet to reduce the risk of stroke in patients with atrial fibrillation and treatment of other conditions.

Daiichi Sankyo announced the submission of a new drug application for Savaysa (edoxaban). The company also is hoping to get the FDA's approval for the pill as a treatment for deep vein thrombosis and pulmonary embolism, as well as preventing the recurrence of symptomatic venous thromboembolism.

January 8, 2014

The Food and Drug Administration has approved a new drug made by Bristol-Myers Squibb and AstraZeneca for treating Type 2 diabetes, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Bristol-Myers Squibb and AstraZeneca for treating Type 2 diabetes, the agency said Wednesday.

The FDA announced the approval of Farxiga (dapagliflozin) tablets, designed for use with exercise and dietary adjustments to control blood sugar. Type 2 diabetes affects about 24 million people in the United States, accounting for more than 90% of diabetes cases.

January 8, 2014

Generic drug maker Mylan has hired a former Pfizer executive to its executive leadership team.

PITTSBURGH — Generic drug maker Mylan has hired a former Pfizer executive to its executive leadership team.

The company announced Wednesday the appointment of Adele Gulf as EVP global collaboration and strategic operations. Before working for Mylan, Gulfo served as regional president of Latin America for Pfizer's Emerging Markets Business Unit, overseeing more than 4,000 employees in 23 countries and achieving more than $3 billion in sales in Latin America in 2012.

January 8, 2014

Takeda Pharmaceutical has started a late-stage clinical trial program of its experimental drug for inflammatory bowel disease in Japan, the company said Wednesday.

OSAKA, Japan — Takeda Pharmaceutical has started a late-stage clinical trial program of its experimental drug for inflammatory bowel disease in Japan, the company said Wednesday.

Takeda announced the start of two phase-3 trials of MLN0002 (vedolizumab) in patients with severe ulcerative colitis and Crohn's disease. The trials are designed to find out the efficacy, safety and effects on the body of the drug, particularly to see if patients show a response after 10 weeks of treatment and disease remission after 60 weeks.

January 7, 2014

Ani Pharmaceuticals has bought 31 generic drugs from Teva Pharmaceuticals for $12.5 million, the company said.

BAUDETTE, Minn. — Ani Pharmaceuticals has bought 31 generic drugs from Teva Pharmaceuticals for $12.5 million, the company said.

January 7, 2014

Growth in health spending has slowed in recent years, including spending by private and public payers, according to data released by the Centers for Medicare and Medicaid Services that also found a small contribution to the lower growth from the healthcare reform law.

WASHINGTON — Growth in health spending has slowed in recent years, including spending by private and public payers, according to data released Monday by the Centers for Medicare and Medicaid Services that also found a small contribution to the lower growth from the healthcare reform law.

January 7, 2014

Mylan has launched a generic version of a drug made by Pfizer for treating bladder problems, the company said Tuesday.

PITTSBURGH — Mylan has launched a generic version of a drug made by Pfizer for treating bladder problems, the company said Tuesday.

Mylan announced the launch of tolterodine tartrate extended-release capsules in the 2-mg and 4-mg strengths. The drug is used to treat overactive bladder with symptoms of urinary incontinence, urgency and frequency.

The drug is a generic version of Pfizer's Detrol LA. Tolterodine tartrate extended-release capsules had sales of about $571.5 million during the 12-month period that ended in September, according to IMS Health.

January 6, 2014

The ability of most accountable care organizations to promote optimal use of medications has not yet been developed, according to a new study.

WASHINGTON — The ability of accountable care organizations to promote optimal use of medications has not yet been fully developed, according to a new study.